Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | NAMPT | P43490 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19725924 | 1.00 | OPRM1 (0.38) | OPRM1OPRK1KMT2ALMNANAMPT | |
| SCHEMBL25820270 | 0.95 | OPRM1 (0.38) | OPRM1OPRK1KMT2ALMNANAMPT | |
| SCHEMBL25144485 | 0.86 | OPRM1 (0.36) | OPRM1OPRK1KMT2ALMNANAMPT | |
| SCHEMBL25822542 | 0.85 | OPRM1 (0.33) | OPRM1OPRK1LMNA | |
| SCHEMBL6855086 | 0.77 | — | — | |
| SCHEMBL19122812 | 0.75 | NAMPT (0.32) | NAMPT | |
| SCHEMBL16659569 | 0.75 | NAMPT (0.32) | NAMPT | |
| SCHEMBL13067273 | 0.75 | OPRM1 (0.41) | OPRM1OPRK1KMT2ALMNA | |
| SCHEMBL19424166 | 0.75 | OPRM1 (0.41) | OPRM1OPRK1KMT2ALMNA | |
| SCHEMBL16984331 | 0.74 | NAMPT (0.42) | NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3919494-B1 | JANUS KINASE (JAK) FAMILY INHIBITOR, PREPARATION OF SAME, AND APPLICATIONS THEREOF | JIANGSU VCARE PHARMATECH CO LTD (CN) | 2023-05-24 | — | — | EP | disclosed |
| US-20220177467-A1 | Janus Kinase (JAK) Family Inhibitor, Preparation of Same, and Applications Thereof | JIANGSU VCARE PHARMATECH CO., LTD. (CN) | 2022-06-09 | — | — | US | disclosed |
| EP-3919494-A1 | JANUS KINASE (JAK) FAMILY INHIBITOR, PREPARATION OF SAME, AND APPLICATIONS THEREOF | Jiangsu Vcare Pharmatech Co., Ltd (CN) | 2021-12-08 | — | — | EP | disclosed |
| WO-2020156271-A1 | JANUS KINASE (JAK) FAMILY INHIBITOR, PREPARATION OF SAME, AND APPLICATIONS THEREOF | 江苏威凯尔医药科技有限公司 | 2020-08-06 | — | — | WO | disclosed |
| WO-2020132648-A1 | KIF18A INHIBITORS | AMGEN INC. (US) | 2020-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220177467-A1 | Janus Kinase (JAK) Family Inhibitor, Preparation of Same, and Applications Thereof | JAK1, JAK3, JAK2 | OPRM1 3865/4885OPRK1 1760/4885KMT2A 648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.